Molecure S.A. (1B1.F)
| Previous Close | 3.3200 |
| Open | 3.3550 |
| Bid | 3.3200 x N/A |
| Ask | 3.3900 x N/A |
| Day's Range | 3.3550 - 3.3550 |
| 52 Week Range | 3.2950 - 5.3500 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 58.253M |
| Beta (5Y Monthly) | 2.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireMolecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).World's first administration of a chitotriosidase 1 inhibitor (or placebo) to a patient with active pulmonary sarcoidosis as part of the Phase II OATD-01 clinical trial (proof-of-concept in human) at a hospital in the UK.First success in mRNA platform development -
- GlobeNewswire
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or placebo (in tablet form) for 12 weeks - The double-blind, randomised, placebo-controlled study is designed to determine the clinical efficacy, pharmacokinetics, pharmacodynamics and safety of OATD-01 - The Phase
- GlobeNewswire
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
U.S. Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial for novel chitinase inhibitor OATD-01 in pulmonary sarcoidosis with first patient expected to be dosed in fourth quarter of 2023 Continued enrollment in the Phase I clinical trial of OATD-02, an oral, first in class dual arginase inhibitor for the treatment of cancer with initial data expected early 2024Successful Secondary Public Offering (SPO) raising gross proceeds of approximately PLN50 million (USD12 milli
